Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma

Journal of Clinical Investigation

Volumn 122, Issue 7, 2012, Pages 2554-2566

  Ruan, Yuanyuan ^a,b   Sun, Linlin ^a,b   Hao, Yuqing ^a,b   Wang, Lijing ^a,b   Xu, Jiejie ^a,b   Zhang, Wen ^c,d   Xie, Jianhui ^a,b   Guo, Liang ^a,b   Zhou, Lei ^a,b   Yun, Xiaojing ^a,b   Zhu, Hongguang ^b,c   Shen, Aiguo ^e   Gu, Jianxin ^a,b,c  

^a BEIJING HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NANTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E; RECEPTOR FOR ACTIVATED C KINASE 1;

ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; UPREGULATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EUKARYOTIC INITIATION FACTOR-4E; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEINS; HUMANS; LIVER; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; PROTEIN KINASE C; RECEPTORS, CELL SURFACE; RIBOSOMAL PROTEINS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863549085     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI58488     Document Type: Article

References (67)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int J Cancer. 2001;94(2):153-156. (Pubitemid 32911406)
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907-1917. (Pubitemid 37518510)
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-1236. (Pubitemid 43112690)
4. Okada S. Chemotherapy in hepatocellular carcinoma. Hepatogastroenterology. 1998;45(suppl 3):1259-1263. (Pubitemid 28372110)
5. Kawai S, et al. Prospective and randomized trial of lipiodol- transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol. 1997;24(2 suppl 6):S6-38-S6-45.
6. Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer. 2003;3(3):179-192. (Pubitemid 37328870)
7. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer. 2010;10(4):254-266.
8. Sonenberg N, Pause A. Signal transduction. Protein synthesis and oncogenesis meet again. Science. 2006;314(5798):428-429. (Pubitemid 44628952)
9. Kapp LD, Lorsch JR. The molecular mechanics of eukaryotic translation. Annu Rev Biochem. 2004;73:657-704. (Pubitemid 39050383)
10. Gebauer F, Hentze MW. Molecular mechanisms of translational control. Nat Rev Mol Cell Biol. 2004;5(10):827-835. (Pubitemid 39336276)
11. Holcik M, Sonenberg N. Translational control in stress and apoptosis. Nat Rev Mol Cell Biol. 2005;6(4):318-327. (Pubitemid 40516898)
12. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004;23(18):3189-3199. (Pubitemid 38638830)
13. Mamane Y, et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One. 2007;2(2):e242.
14. Graff JR, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest. 2007;117(9):2638-2648. (Pubitemid 47494364)
15. Meric F, Hunt KK. Translation initiation in cancer: a novel target for therapy. Mol Cancer Ther. 2002;1(11):971-979.
16. Tam KH, Yang ZF, Lau CK, Lam CT, Pang RW, Poon RT. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett. 2009;273(2):201-209.
17. Mondesire WH, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004;10(20):7031-7042. (Pubitemid 39383055)
18. Bordeleau ME, et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest. 2008;118(7):2651-2660.
19. Cencic R, Carrier M, Trnkus A, Porco JA Jr, Minden M, Pelletier J. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res. 2010;34(4):535-541.
20. Ron D, Chen CH, Caldwell J, Jamieson L, Orr E, Mochly-Rosen D. Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins. Proc Natl Acad Sci U S A. 1994;91(3):839-843. (Pubitemid 24048462)
21. McCahill A, Warwicker J, Bolger GB, Houslay MD, Yarwood SJ. The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. Mol Pharmacol. 2002;62(6):1261-1273. (Pubitemid 35403822)
22. Link AJ, et al. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol. 1999;17(7):676-682. (Pubitemid 29316146)
23. Sengupta J, Nilsson J, Gursky R, Spahn CM, Nissen P, Frank J. Identification of the versatile scaffold protein RACK1 on the eukaryotic ribosome by cryo-EM. Nat Struct Mol Biol. 2004;11(10):957-962. (Pubitemid 39315299)
24. Baum S, Bittins M, Frey S, Seedorf M. Asc1p, a WD40-domain containing adaptor protein, is required for the interaction of the RNA-binding protein Scp160p with polysomes. Biochem J. 2004;380(pt 3):823-830. (Pubitemid 38850524)
25. Berns H, Humar R, Hengerer B, Kiefer FN, Battegay EJ. RACK1 is up-regulated in angiogenesis and human carcinomas. FASEB J. 2000;14(15):2549- 2558.
26. Wang Z, et al. RACK1, an excellent predictor for poor clinical outcome in oral squamous carcinoma, similar to Ki67. Eur J Cancer. 2009;45(3):490-496.
27. Nagashio R, et al. Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas. Lung Cancer. 2010;69(1):54-59.
28. Cao XX, et al. RACK1: A superior independent predictor for poor clinical outcome in breast cancer. Int J Cancer. 2010;127(5):1172-1179.
29. Myklebust LM, Akslen LA, Varhaug JE, Lillehaug JR. Receptor for activated protein C kinase 1 (RACK1) is overexpressed in papillary thyroid carcinoma. Thyroid. 2011;21(11):1217-1225.
30. Zhang W, et al. RACK1 and CIS mediate the degradation of BimEL in cancer cells. J Biol Chem. 2008;283(24):16416-16426.
31. Lopez-Bergami P, Habelhah H, Bhoumik A, Zhang W, Wang LH, Ronai Z. RACK1 mediates activation of JNK by protein kinase C [corrected]. Mol Cell. 2005;19(3):309-320. (Pubitemid 41074887)
32. Kiely PA, Baillie GS, Lynch MJ, Houslay MD, O'Connor R. Tyrosine 302 in RACK1 is essential for insulin-like growth factor-I-mediated competitive binding of PP2A and beta1 integrin and for tumor cell proliferation and migration. J Biol Chem. 2008;283(34):22952-22961.
33. Kiely PA, et al. Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for insulin-like growth factor I-mediated regulation of focal adhesion kinase. J Biol Chem. 2009;284(30):20263-20274.
34. Mamidipudi V, Zhang J, Lee KC, Cartwright CA. RACK1 regulates G1/S progression by suppressing Src kinase activity. Mol Cell Biol. 2004;24(15):6788-6798. (Pubitemid 38944357)
35. Arimoto K, Fukuda H, Imajoh-Ohmi S, Saito H, Takekawa M. Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways. Nat Cell Biol. 2008;10(11):1324-1332.
36. Ceci M, et al. Release of eIF6 (p27BBP) from the 60S subunit allows 80S ribosome assembly. Nature. 2003;426(6966):579-584. (Pubitemid 37522646)
37. Shor B, Calaycay J, Rushbrook J, McLeod M. Cpc2/RACK1 is a ribosome-associated protein that promotes efficient translation in Schizosaccharomyces pombe. J Biol Chem. 2003;278(49):49119-49128.
38. Gerbasi VR, Weaver CM, Hill S, Friedman DB, Link AJ. Yeast Asc1p and mammalian RACK1 are functionally orthologous core 40S ribosomal proteins that repress gene expression. Mol Cell Biol. 2004;24(18):8276-8287. (Pubitemid 39167475)
39. Hao Y, et al. CDK11p46 and RPS8 associate with each other and suppress translation in a synergistic manner. Biochem Biophys Res Commun. 2011;407(1):169-174.
40. Nilsson J, Sengupta J, Frank J, Nissen P. Regulation of eukaryotic translation by the RACK1 protein: a platform for signalling molecules on the ribosome. EMBO Rep. 2004;5(12):1137-1141. (Pubitemid 40103606)
41. Ron D, Jiang Z, Yao L, Vagts A, Diamond I, Gordon A. Coordinated movement of RACK1 with activated betaIIPKC. J Biol Chem. 1999;274(38):27039-27046.
42. Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J. 1999;18(1):270-279. (Pubitemid 29005042)
43. Haghighat A, Mader S, Pause A, Sonenberg N. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J. 1995;14(22):5701-5709.
44. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK. Cocrystal structure of the messenger RNA 5′ cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell. 1997;89(6):951-961. (Pubitemid 27513521)
45. Rabl J, Leibundgut M, Ataide SF, Haag A, Ban N. Crystal structure of the eukaryotic 40S ribosomal subunit in complex with initiation factor 1. Science. 2011;331(6018):730-736.
46. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol. 2004;24(15):6539-6549. (Pubitemid 38944335)
47. Gausdal G, et al. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood. 2008;111(5):2866-2877.
48. Robert F, Carrier M, Rawe S, Chen S, Lowe S, Pelletier J. Altering chemosensitivity by modulating translation elongation. PLoS One. 2009;4(5):e5428.
49. Xu J, et al. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma via reducing Notch1 cleavage. Hepatology. 2010;52(1):142-154.
50. Wei Y, et al. Identification of beta-1,4-galactosyltransferase I as a target gene of HBx-induced cell cycle progression of hepatoma cell. J Hepatol. 2008;49(6):1029-1037.
51. Liu H, et al. Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res. 2011;71(24):7547-7557.
52. Ohn T, Kedersha N, Hickman T, Tisdale S, Anderson P. A functional RNAi screen links O-GlcNAc modification of ribosomal proteins to stress granule and processing body assembly. Nat Cell Biol. 2008;10(10):1224-1231.
53. Holcik M, Sonenberg N, Korneluk RG. Internal ribosome initiation of translation and the control of cell death. Trends Genet. 2000;16(10):469-473.
54. Graber TE, Holcik M. Cap-independent regulation of gene expression in apoptosis. Mol Biosyst. 2007;3(12):825-834. (Pubitemid 350115410)
55. Wendel HG, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007;21(24):3232-3237.
56. Metzger E, et al. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4. Nature. 2010;464(7289):792-796.
57. Villanueva A, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135(6):1972-1983.
58. Vomastek T, Iwanicki MP, Schaeffer HJ, Tarcsafalvi A, Parsons JT, Weber MJ. RACK1 targets the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to link integrin engagement with focal adhesion disassembly and cell motility. Mol Cell Biol. 2007;27(23):8296-8305. (Pubitemid 350234241)
59. Cao XX, et al. RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo. Breast Cancer Res Treat. 2010;123(2):375-386.
60. Wang F, Yamauchi M, Muramatsu M, Osawa T, Tsuchida R, Shibuya M. RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3-K/Akt pathway. J Biol Chem. 2011;286(11):9097-9106.
61. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5(3):215-219. (Pubitemid 38402113)
62. Forner A, Real MI, Varela M, Bruix J. Transarterial chemoembolization for patients with hepatocellular carcinoma. Hepatol Res. 2007;37(suppl 2):S230-S237.
63. Liu L, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851-11858. (Pubitemid 46094197)
64. Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.
65. Abou-Alfa GK, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304(19):2154-2160.
66. Marash L, et al. DAP5 promotes cap-independent translation of Bcl-2 and CDK1 to facilitate cell survival during mitosis. Mol Cell. 2008;30(4):447-459.
67. Kamijo T, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997;91(5):649-659. (Pubitemid 27513656)